Medtronic, a global leader in healthcare technology, announced a partnership with Methinks AI, a leading AI-driven radiological triage and notification system provider to enhance stroke treatment across Central and Eastern Europe, Africa, Türkiye and Middle East, supporting its Neurovascular business. Financial terms of the partnership were not disclosed.

This collaboration highlights the critical role of services and solutions in optimizing procedural support and patient pathways in stroke care.

For Medtronic, this partnership aligns with its commitment to delivering cutting-edge innovations in acute ischemic stroke treatment. Medtronic has been at the forefront of stroke therapy with its advanced stent retrievers and aspiration systems for clot retrieval. Methinks AI-powered solutions supports healthcare professionals with stroke assessment, ultimately helping to save critical time in patient management.

Methinks AI solutions, which has already been validated in renowned hospitals across Europe and the U.S., stands out for its ability to detect over 80% of large vessel occlusions using only non-contrast CT imaging. This capability ensures faster assessment, even in settings with limited access to advanced imaging technologies, reducing critical delays in treatment. Furthermore, Methinks AI has partnered with Microsoft to enhance the scalability and accessibility of this technology.

By integrating Methinks AI with Medtronic stroke treatment portfolio, the partnership will streamline the connectivity between stroke centers and regional hospitals in the region, enabling seamless patient triage and care coordination. The software capability to assess strokes directly from a non-contrast CT scan will empower healthcare providers with timely decision-making tools.

The future of stroke management

This collaboration marks a significant step in patient pathway development for medical centers in the region. The integration of AI-driven stroke assessment with Medtronic Neurovascular products is expected to accelerate therapy adoption, bringing stroke treatment to a new level of efficiency.

“At Medtronic, we are committed to providing innovative solutions that extend beyond traditional product offerings. This partnership reinforces our commitment to support healthcare professionals with advanced stroke care tools, ensuring faster and more effective treatment for patients across the region and transforming stroke care by combining breakthrough AI assessment with world-class medical device solutions”, said Maria Zvereva, Neurovascular strategic marketing leader in CEMA region, which is part of the Neuroscience Portfolio at Medtronic.

"We are honored to collaborate with Medtronic, a company that shares our commitment to increasing the number of stroke treatments available to those that urgently need them. Together, we aim to bring our AI-driven solutions to more hospitals to benefit from early triage and efficient coordination," said Pau Rodríguez, CEO of Methinks.

About Methinks AI
Methinks AI is a pioneering company in the development of artificial intelligence software for the early assessment of stroke. It is the first CE-marked medical device capable of detecting large vessel occlusions, both hyperdense and non-hyperdense, as well as intracerebral hemorrhages using non-contrast computed tomography. This technology helps optimize stroke patient triage and reduce time to treatment, significantly improving clinical outcomes.

About Medtronic 
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow us on LinkedIn. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Malgorzata Kolodrub
Public Relations
+0048 887 856 679

Ryan Weispfenning
Investor Relations
+1-763-505-4626